WHAT IS CLAIMED IS:

1. Use of a JAK1 pathway inhibitor, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of asthma in a subject, wherein the asthma is noneosinophilic asthma.

2. The use of claim 1, wherein the JAK1 pathway inhibitor, or a pharmaceutically acceptable salt thereof, is selective for JAK1 over JAK2, JAK3, and Tyk2.

3. The use of claim 1, wherein the JAK1 pathway inhibitor is 4-[3-(cyanomethyl)-3-(3',5'-dimethyl-1H,1'H-4,4'-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide, or a pharmaceutically acceptable salt thereof.

4. The use of claim 1, wherein the JAK1 pathway inhibitor is 4-[3-(cyanomethyl)-3-(3',5'-dimethyl-1H,1'H-4,4'-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide phosphoric acid salt.

5. The use of any one of claims 1-4, wherein the medicament comprising the JAK1 pathway inhibitor, or pharmaceutically acceptable salt thereof, is to be administered in a daily dose of about 10 mg to about 80 mg on a free base basis.

6. The use of any one of claims 1-5, wherein the medicament is formulated for oral administration.

7. The use of any one of claims 1-6, wherein medicament is formulated for oral administration via tablet.

8. The use of any one of claims 1-7, wherein the medicament comprising the JAK1 pathway inhibitor, or pharmaceutically acceptable salt thereof, is to be administered in a daily dose of about 15 mg, about 45 mg, or about 75 mg on a free base basis.

9. The use of any one of claims 1-8, wherein the medicament comprising the JAK1 pathway inhibitor, or pharmaceutically acceptable salt thereof, is to be administered in combination with a further therapeutic agent.

10. The use of claim 9, wherein the further therapeutic agent comprises a Janus kinase inhibitor.

11. The use of claim 10, wherein the Janus kinase inhibitor comprises ruxolitinib, or a pharmaceutically acceptable salt thereof.

12. The use of any one of claims 1-11, wherein the medicament comprises at least one pharmaceutically acceptable carrier or excipient.

13. The use of claim 1, wherein the medicament comprising the JAK1 pathway inhibitor or pharmaceutically acceptable salt thereof is to be administered to the subject and results in the subject having about a 10% increase or greater in lung function after administration of the medicament based on FEV_1.

14. The use of claim 1, wherein the medicament comprising the JAK1 pathway inhibitor or pharmaceutically acceptable salt thereof is to be administered to the subject and results in the subject having a decrease in a number of inpatient hospitalization events due to asthma after administration of the medicament, wherein the decrease is about a 30%, about a 60%, or about a 90% reduction in the number of inpatient hospitalization events due to asthma.

15. The use of claim 14, wherein the inpatient hospitalization event comprises admission to an inpatient facility or healthcare facility for $\geq$ 24 hours.

16. The use of claim 1, wherein the medicament comprising the JAK1 pathway inhibitor or pharmaceutically acceptable salt thereof is to be administered to the subject and results in the subject having about a 10% increase or greater in lung function after administration of the medicament based on FVC.

17. The use of claim 1, wherein the medicament comprising the JAK1 pathway inhibitor or pharmaceutically acceptable salt thereof is to be administered to the subject and results in the subject having about a 10% improvement or greater in lung function after administration of the medicament based on FeNO.

18. The use of claim 1, wherein the medicament comprising the JAK1 pathway inhibitor or pharmaceutically acceptable salt thereof is to be administered to the subject and

results in the subject having about a 10% increase or greater in lung function after administration of the medicament based on a PEF test result.

19. Use of a JAK1 pathway inhibitor in the manufacture of a medicament for the treatment of asthma.